# A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

**This study has been completed.**

Study NCT00158600 Information provided by Genzyme
Study First Received: September 8, 2005 Last Updated: June 24, 2010 History of Changes
Results First Received: June 24, 2010

| | |
|---|---|
| **Study Type:** | Interventional |
| **Study Design:** | Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study;<br>Intervention Model: Parallel Assignment;<br>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);<br>Primary Purpose: Treatment |
| **Conditions:** | **Pompe** Disease (Late-onset)<br>Glycogen Storage Disease Type II (GSD-II)<br>Acid Maltase Deficiency Disease<br>Glycogenosis 2 |
| **Interventions:** | Biological: alglucosidase alfa<br>Drug: Placebo |

## Participant Flow

Hide Participant Flow

**Recruitment Details**

| **Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations** |
|---|
| No text entered. |

**Pre-Assignment Details**

| **Significant events and approaches for the overall study following participant enrollment, but prior to group assignment** |
|---|
| One hundred patients screened and 90 enrolled. |

**Reporting Groups**

| | **Description** |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |
| **Placebo** | Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks. |

**Participant Flow: Overall Study**

| | **Alglucosidase Alfa** | **Placebo** |
|---|---|---|

| | | |
|---|---|---|
| **STARTED** | **60** | **30** |
| **COMPLETED** | **55** | **26** |
| **NOT COMPLETED** | **5** | **4** |
| **unable to commit time to study** | **0** | **1** |
| **Adverse Event** | **2** | **1** |
| **Death** | **1** | **0** |
| **Withdrawal by Subject** | **2** | **2** |

## Baseline Characteristics

Hide Baseline Characteristics

**Reporting Groups**

| | Description |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |
| **Placebo** | Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks. |

**Baseline Measures**

| | Alglucosidase Alfa | Placebo | Total |
|---|---|---|---|
| **Number of Participants** [units: participants] | **60** | **30** | **90** |
| **Age** [1] [units: years] Mean ± Standard Deviation | **45.3 ± 12.37** | **42.6 ± 11.63** | **44.4 ± 12.14** |
| **Gender** [units: participants] | | | |
| **Female** | **26** | **19** | **45** |
| **Male** | **34** | **11** | **45** |
| **Race/Ethnicity, Customized** [units: participants] | | | |
| **Hispanic** | **1** | **1** | **2** |
| **Asian** | **1** | **1** | **2** |
| **Black or African American** | **0** | **0** | **0** |
| **White** | **57** | **27** | **84** |
| **Unknown or not reported** | **1** | **1** | **2** |

[1] Age at First Infusion

## Outcome Measures

Hide All Outcome Measures

### 1. Primary: Summary of Patients Reporting Treatment-Emergent Adverse Events [ Time Frame: weeks 0-78 ]

| | |
|---|---|
| **Measure Type** | Primary |
| **Measure Title** | Summary of Patients Reporting Treatment-Emergent Adverse Events |

| | |
|---|---|
| **Measure Description** | Overall safety summary of patients experiencing Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, and Infusion Associated Reactions (IARs). Summary is based on Treatment-emergent AEs (TEAEs), defined as AEs that occurred following the initiation of study treatment, i.e., alglucosidase alfa or placebo. |
| **Time Frame** | weeks 0-78 |
| **Safety Issue** | Yes |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| All patients who received any amount of study treatment comprise the safety population. Patients were considered, for safety analysis, to be in the treatment group of the treatment they actually received.<br>Missing or invalid safety or resource utilization data were not replaced. |

**Reporting Groups**

| | **Description** |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |
| **Placebo** | Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks. |

**Measured Values**

| | **Alglucosidase Alfa** | **Placebo** |
|---|---|---|
| **Number of Participants Analyzed**<br>[units: participants] | **60** | **30** |
| **Summary of Patients Reporting Treatment-Emergent Adverse Events**<br>[units: participants] | | |
| **Patients with Any AEs** | **60** | **30** |
| **Patients with Treatment-Related AEs** | **32** | **17** |
| **Patients with Infusion-Associated Reactions** | **17** | **7** |
| **Patients with SAEs** | **13** | **6** |
| **Patients with Severe AEs** | **14** | **10** |
| **Patients who Discontinued Due to AEs (incl death)** | **3** | **1** |
| **Patients who Died** | **1** | **0** |

**No statistical analysis provided for Summary of Patients Reporting Treatment-Emergent Adverse Events**

## 2. Primary: Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From Baseline [ Time Frame: weeks 0, 78 ]

| | |
|---|---|
| **Measure Type** | Primary |
| **Measure Title** | Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From Baseline |

| | |
|---|---|
| **Measure Description** | Mean distance walked gives an indication of functional endurance. The greater the distance, the greater the endurance. Mean values of distance walked in a six-minute walk test are offered for baseline, week 78 (or last available observation), and the mean change from baseline (at week 78 or last available post-baseline observation). |
| **Time Frame** | weeks 0, 78 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| Intent-to-Treat (ITT) population. Last observation carried forward. The last available distance walked for one patient was the Baseline visit; therefore, this patient was excluded from the change from baseline calculation. |

**Reporting Groups**

| | **Description** |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |
| **Placebo** | Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks. |

**Measured Values**

| | **Alglucosidase Alfa** | **Placebo** |
|---|---|---|
| **Number of Participants Analyzed**<br>[units: participants] | **60** | **30** |
| **Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From Baseline**<br>[units: meters]<br>Mean ± Standard Deviation | | |
| **Distance Walked at Baseline** | **332.20 ± 126.69** | **317.93 ± 132.29** |
| **Distance Walked at Last Available Observation** | **357.85 ± 141.32** | **313.07 ± 144.69** |
| **Change at Last Available Observation from Baseline** | **26.08 ± 64.41** | **-4.87 ± 45.24** |

**Statistical Analysis 1 for Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From Baseline**

| | |
|---|---|
| **Groups** [1] | All groups |
| **Method** [2] | ANCOVA |
| **P Value** [3] | 0.0347 |
| **Difference** [4] | 28.12 |
| **95% Confidence Interval** | ( 2.07 to 54.17 ) |

**[1]** Additional details about the analysis, such as null hypothesis and power calculation:

The difference between alglucosidase alfa and placebo treatment groups in change in distance walked from baseline to last observation was estimated by ANCOVA after adjusting for baseline value and randomization strata.

**[2]** Other relevant information, such as adjustments or degrees of freedom:

No text entered.

**[3]** Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

The threshold for determining statistical significance is 0.05. A fixed testing sequence procedure was used to preserve an overall error rate of 5% for the co-primary efficacy endpoints by linking the test of FVC to the result of 6MWT.

**[4]** Other relevant estimation information:

No text entered.

## 3. Primary: Percent of Predicted Forced Vital Capacity (FVC) [ Time Frame: weeks 0, 78 ]

| | |
|---|---|
| **Measure Type** | Primary |
| **Measure Title** | Percent of Predicted Forced Vital Capacity (FVC) |
| **Measure Description** | Forced vital capacity is a standard pulmonary function test used to quantify respiratory muscle weakness. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%. |
| **Time Frame** | weeks 0, 78 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| ITT population. Last observation carried forward. |

**Reporting Groups**

| | **Description** |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |
| **Placebo** | Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks. |

**Measured Values**

| | **Alglucosidase Alfa** | **Placebo** |
|---|---|---|
| **Number of Participants Analyzed** [units: participants] | **60** | **30** |
| **Percent of Predicted Forced Vital Capacity (FVC)** [units: percent predicted FVC] Mean ± Standard Deviation | | |
| **Baseline (week 0)** | **55.43 ± 14.44** | **53.00 ± 15.66** |
| **Week 78 (or last observation)** | **56.71 ± 16.30** | **50.70 ± 14.88** |
| **Change at Week 78 from Baseline** | **1.25 ± 5.55** | **-2.30 ± 4.33** |

**Statistical Analysis 1 for Percent of Predicted Forced Vital Capacity (FVC)**

| | |
|---|---|
| **Groups** [1] | All groups |

| | |
|---|---|
| **Method** [2] | ANCOVA |
| **P Value** [3] | 0.0055 |
| **Difference** [4] | 3.40 |
| **95% Confidence Interval** | ( 1.03 to 5.77 ) |

**[1]** Additional details about the analysis, such as null hypothesis and power calculation:

The difference between alglucosidase alfa and placebo treatment groups in change in % predicted FVC from baseline to last observation was estimated by ANCOVA after adjusting for baseline value and randomization strata.

**[2]** Other relevant information, such as adjustments or degrees of freedom:

No text entered.

**[3]** Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

The threshold for determining statistical significance is 0.05. A fixed testing sequence procedure was used to preserve an overall error rate of 5% for the co-primary efficacy endpoints by linking the test of FVC to the result of 6MWT.

**[4]** Other relevant estimation information:

No text entered.

## 4. Primary: Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC) [ Time Frame: weeks 0, 12 and 52 ]

| | |
|---|---|
| **Measure Type** | Primary |
| **Measure Title** | Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC) |
| **Measure Description** | Area under the plasma concentration versus time curve from time zero (pre-dose) to 16 hours after the end of infusion. Blood sample time points were 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion). Pooled figures combine the values for the three timeframes. |
| **Time Frame** | weeks 0, 12 and 52 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The subgroup of patients for whom pharmacokinetic samples were obtained was based on those study sites that could accommodate pharmacokinetic sampling needs. |

**Reporting Groups**

| | **Description** |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |

**Measured Values**

| | **Alglucosidase Alfa** |
|---|---|
| **Number of Participants Analyzed** [units: participants] | **32** |

| | |
|---|---|
| **Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC)**<br>[units: ug*h/mL]<br>Mean ± Standard Deviation | |
| **Week 0** | **2672.47 ± 1139.85** |
| **Week 12** | **2386.76 ± 555.09** |
| **Week 52** | **2699.28 ± 999.97** |
| **Pooled** | **2586.17 ± 933.28** |

**No statistical analysis provided for Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC)**

## 5. Primary: Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration(Cmax) [ Time Frame: weeks 0, 12, 52 ]

| | |
|---|---|
| **Measure Type** | Primary |
| **Measure Title** | Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration(Cmax) |
| **Measure Description** | Maximum plasma concentration observed in blood samples taken at the following time points: 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion). Pooled figures combine the values for the three timeframes. |
| **Time Frame** | weeks 0, 12, 52 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The subgroup of patients for whom pharmacokinetic samples were obtained was based on those study sites that could accommodate pharmacokinetic sampling needs. |

**Reporting Groups**

| | **Description** |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |

**Measured Values**

| | **Alglucosidase Alfa** |
|---|---|
| **Number of Participants Analyzed**<br>[units: participants] | **32** |
| **Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration (Cmax)**<br>[units: ng/mL]<br>Mean ± Standard Deviation | |

| | |
|---|---|
| **Week 0** | **385237 ± 105585** |
| **Week 12** | **349269 ± 78620** |
| **Week 52** | **369744 ± 88203** |
| **Pooled** | **368083 ± 91721** |

**No statistical analysis provided for Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration(Cmax)**

## 6. Primary: Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax) [ Time Frame: weeks 0, 12, 52 ]

| | |
|---|---|
| **Measure Type** | Primary |
| **Measure Title** | Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax) |
| **Measure Description** | Time to maximum plasma concentration observed in blood samples taken at the following time points: 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion). Pooled figures combine the values for the three timeframes. |
| **Time Frame** | weeks 0, 12, 52 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| The subgroup of patients for whom pharmacokinetic samples were obtained was based on those study sites that could accommodate pharmacokinetic sampling needs. |

**Reporting Groups**

| | **Description** |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |

**Measured Values**

| | **Alglucosidase Alfa** |
|---|---|
| **Number of Participants Analyzed** [units: participants] | **32** |
| **Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax)** [units: hours] Mean ± Standard Deviation | |
| **Week 0** | **3.62 ± 0.33** |
| **Week 12** | **3.62 ± 0.28** |

| | |
|---|---|
| **Week 52** | **3.64 ± 0.31** |
| **Pooled** | **3.63 ± 0.30** |

**No statistical analysis provided for Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax)**

## 7. Secondary: Percent Predicted Proximal Muscle Strength of the Lower Limbs as Measured by Quantitative Muscle Testing (QMT) [ Time Frame: weeks 0, 78 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Percent Predicted Proximal Muscle Strength of the Lower Limbs as Measured by Quantitative Muscle Testing (QMT) |
| **Measure Description** | Quantitative muscle testing (QMT) is a standardized system to measure muscle force production during maximal voluntary isometric contraction. QMT data were collected directly from sensors into laptop computers. Predicted normal values for QMT are based on a formula using sex, age and body mass index of a person, and is an estimate of healthy muscle force. Percent of predicted QMT = (observed value)/(predicted value) * 100%. The QMT Leg Score is the average of the bilateral means for percent predicted knee flexors and extensors. A value of 100% indicates 'normal' muscle strength. |
| **Time Frame** | weeks 0, 78 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| ITT population. Last observation carried forward. |

**Reporting Groups**

| | **Description** |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |
| **Placebo** | Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks. |

**Measured Values**

| | **Alglucosidase Alfa** | **Placebo** |
|---|---|---|
| **Number of Participants Analyzed** [units: participants] | **60** | **30** |
| **Percent Predicted Proximal Muscle Strength of the Lower Limbs as Measured by Quantitative Muscle Testing (QMT)** [units: percent predicted QMT] Mean ± Standard Deviation | | |
| **Baseline (week 0)** | **37.69 ± 18.88** | **32.49 ± 18.24** |
| **Week 78 (or last available observation)** | **39.05 ± 21.83** | **30.40 ± 20.54** |
| **Change at Week 78 from Baseline** | **1.22 ± 9.88** | **-2.08 ± 5.11** |

**Statistical Analysis 1 for Percent Predicted Proximal Muscle Strength of the Lower Limbs as Measured by Quantitative Muscle Testing (QMT)**

| | |
|---|---|
| **Groups** [1] | All groups |
| **Method** [2] | ANCOVA |
| **P Value** [3] | 0.1093 |
| **Difference** [4] | 3.18 |
| **95% Confidence Interval** | ( -0.73 to 7.08 ) |

**[1]** Additional details about the analysis, such as null hypothesis and power calculation:

The difference between alglucosidase alfa and placebo treatment groups in change in QMT from baseline to last observation was estimated by ANCOVA after adjusting for baseline value and randomization strata.

**[2]** Other relevant information, such as adjustments or degrees of freedom:

No text entered.

**[3]** Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

The threshold for determining statistical significance is 0.05. No adjustment for multiple comparison was made for secondary efficacy endpoints.

**[4]** Other relevant estimation information:

No text entered.

## 8. Secondary: Health-related Quality of Life Survey Values Related to Physical Components as Measured by the Medical Outcomes Study (MOS) Short Form-36 Health Survey [ Time Frame: weeks 0, 78 ]

| | |
|---|---|
| **Measure Type** | Secondary |
| **Measure Title** | Health-related Quality of Life Survey Values Related to Physical Components as Measured by the Medical Outcomes Study (MOS) Short Form-36 Health Survey |
| **Measure Description** | The Medical Outcomes Study Short Form (MOS SF)-36 questionnaire consists of 36 items grouped into 8 domains designed to assess generic health-related quality of life in healthy and ill adult populations. Physical Component Scores (PCS) report the four domains of physical functioning, role-physical, bodily pain, and general health. Higher scores are associated with better quality of life. All questions are scored on a scale from 0 to 100, with 100 representing the highest level of functioning possible. The PCS scores are reported. |
| **Time Frame** | weeks 0, 78 |
| **Safety Issue** | No |

**Population Description**

| **Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.** |
|---|
| ITT population. Last observation carried forward. |

**Reporting Groups**

| | **Description** |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |

| | |
|---|---|
| **Placebo** | Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks. |

**Measured Values**

| | Alglucosidase Alfa | Placebo |
|---|---|---|
| **Number of Participants Analyzed**<br>[units: participants] | **60** | **30** |
| **Health-related Quality of Life Survey Values Related to Physical Components as Measured by the Medical Outcomes Study (MOS) Short Form-36 Health Survey**<br>[units: Units on a scale]<br>Mean ± Standard Deviation | | |
| **PCS at Baseline (week 0)** | **34.33 ± 8.93** | **34.91 ± 7.26** |
| **PCS at Week 78 (or last available observation)** | **35.11 ± 9.84** | **36.47 ± 9.57** |

**Statistical Analysis 1 for Health-related Quality of Life Survey Values Related to Physical Components as Measured by the Medical Outcomes Study (MOS) Short Form-36 Health Survey**

| | |
|---|---|
| **Groups** [1] | All groups |
| **Method** [2] | ANCOVA |
| **P Value** [3] | 0.8333 |
| **Difference** [4] | -0.37 |
| **95% Confidence Interval** | ( -3.83 to 3.09 ) |

**[1]** Additional details about the analysis, such as null hypothesis and power calculation:

The difference between alglucosidase alfa and placebo treatment groups in change in PCS from baseline to last observation was estimated by ANCOVA after adjusting for baseline value and randomization strata.

**[2]** Other relevant information, such as adjustments or degrees of freedom:

No text entered.

**[3]** Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:

The threshold for determining statistical significance is 0.05. No adjustment for multiple comparison was made for secondary efficacy endpoints.

**[4]** Other relevant estimation information:

No text entered.

## Serious Adverse Events

Hide Serious Adverse Events

| | |
|---|---|
| **Time Frame** | No text entered. |
| **Additional Description** | In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator ("number of affected participants") of both adverse event tables. Events are listed independent of relationship to treatment reported. |

**Reporting Groups**

| | Description |
|---|---|

| | |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |
| **Placebo** | Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks. |
| **Overall** | No text entered. |

**Serious Adverse Events**

| | Alglucosidase Alfa | Placebo | Overall |
|---|---|---|---|
| **Total, serious adverse events** | | | |
| **# participants affected / at risk** | **13/60 (21.67%)** | **6/30 (20.00%)** | **19/90 (21.11%)** |
| **Cardiac disorders** | | | |
| **Coronary artery disease † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Supraventricular tachycardia † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Gastrointestinal disorders** | | | |
| **Abdominal pain † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Abdominal pain upper † 1** | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **General disorders** | | | |
| **Chest discomfort † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Non-cardiac chest pain † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Immune system disorders** | | | |
| **Hypersensitivity † 1** | | | |
| **# participants affected / at risk** | **2/60 (3.33%)** | **0/30 (0.00%)** | **2/90 (2.22%)** |
| **Infections and infestations** | | | |
| **Diverticulitis † 1** | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Gastroenteritis † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Pneumonia † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Injury, poisoning and procedural complications** | | | |
| **Fall † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **1/30 (3.33%)** | **2/90 (2.22%)** |
| **Humerus fracture † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **1/30 (3.33%)** | **2/90 (2.22%)** |
| **Metabolism and nutrition disorders** | | | |
| **Dehydration † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Musculoskeletal and connective tissue disorders** | | | |

| | | | |
|---|---|---|---|
| **Flank pain † 1** | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Intervertebral disc protrusion † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Nervous system disorders** | | | |
| **Brain stem ischaemia † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Headache † 1** | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Respiratory, thoracic and mediastinal disorders** | | | |
| **Lung disorder † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Throat tightness † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Skin and subcutaneous tissue disorders** | | | |
| **Angioneurotic oedema † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Septal panniculitis † 1** | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Vascular disorders** | | | |
| **Aneurysm † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |

† Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 9.1

## Other Adverse Events

Hide Other Adverse Events

| | |
|---|---|
| **Time Frame** | No text entered. |
| **Additional Description** | In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator ("number of affected participants") of both adverse event tables. Events are listed independent of relationship to treatment reported. |

**Frequency Threshold**

| | |
|---|---|
| **Threshold above which other adverse events are reported** | 0% |

**Reporting Groups**

| | **Description** |
|---|---|
| **Alglucosidase Alfa** | Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks. |
| **Placebo** | Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks. |
| **Overall** | No text entered. |

Other Adverse Events

| | Alglucosidase Alfa | Placebo | Overall |
|---|---|---|---|
| **Total, other (not including serious) adverse events** | | | |
| # participants affected / at risk | 60/60 | 30/30 | 90/90 |
| **Blood and lymphatic system disorders** | | | |
| Anaemia † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Lymphadenopathy † 1 | | | |
| # participants affected / at risk | 5/60 (8.33%) | 0/30 (0.00%) | 5/90 (5.56%) |
| Macrocytosis † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Normochromic normocytic anaemia † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| **Cardiac disorders** | | | |
| Angina pectoris † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Bundle branch block left † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Bundle branch block right † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Coronary artery disease † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Palpitations † 1 | | | |
| # participants affected / at risk | 3/60 (5.00%) | 1/30 (3.33%) | 4/90 (4.44%) |
| Sinus tachycardia † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Tachycardia † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Tricuspid valve incompetence † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| **Ear and labyrinth disorders** | | | |
| Auricular swelling † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Ear congestion † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Ear discomfort † 1 | | | |
| # participants affected / at risk | 4/60 (6.67%) | 1/30 (3.33%) | 5/90 (5.56%) |
| Ear pain † 1 | | | |
| # participants affected / at risk | 3/60 (5.00%) | 1/30 (3.33%) | 4/90 (4.44%) |
| Hypoacusis † 1 | | | |
| # participants affected / at risk | 20/60 (33.33%) | 7/30 (23.33%) | 27/90 (30.00%) |
| Presbyacusis † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Tinnitus † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 1/30 (3.33%) | 3/90 (3.33%) |

| | | | |
|---|---|---|---|
| Tympanic membrane disorder [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Tympanic membrane scarring [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Vertigo [†1] | | | |
| # participants affected / at risk | 4/60 (6.67%) | 0/30 (0.00%) | 4/90 (4.44%) |
| **Eye disorders** | | | |
| Altered visual depth perception [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Asthenopia [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Cataract [†1] | | | |
| # participants affected / at risk | 4/60 (6.67%) | 2/30 (6.67%) | 6/90 (6.67%) |
| Conjunctivitis [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Diplopia [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Dry eye [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Eye irritation [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Eye pruritus [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Lacrimation increased [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Photophobia [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Vision blurred [†1] | | | |
| # participants affected / at risk | 3/60 (5.00%) | 0/30 (0.00%) | 3/90 (3.33%) |
| Visual disturbance [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Vitreous floaters [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| **Gastrointestinal disorders** | | | |
| Abdominal discomfort [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 2/30 (6.67%) | 4/90 (4.44%) |
| Abdominal distension [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 2/30 (6.67%) | 3/90 (3.33%) |
| Abdominal mass [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Abdominal pain [†1] | | | |
| # participants affected / at risk | 4/60 (6.67%) | 3/30 (10.00%) | 7/90 (7.78%) |
| Abdominal pain lower [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Abdominal pain upper [†1] | | | |
| # participants affected / at risk | 6/60 (10.00%) | 2/30 (6.67%) | 8/90 (8.89%) |

| | | | |
|---|---|---|---|
| **Constipation** [†1] | | | |
| **# participants affected / at risk** | **6/60 (10.00%)** | **0/30 (0.00%)** | **6/90 (6.67%)** |
| **Dental caries** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Diarrhoea** [†1] | | | |
| **# participants affected / at risk** | **18/60 (30.00%)** | **13/30 (43.33%)** | **31/90 (34.44%)** |
| **Diverticulum** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Dry mouth** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Dyspepsia** [†1] | | | |
| **# participants affected / at risk** | **5/60 (8.33%)** | **0/30 (0.00%)** | **5/90 (5.56%)** |
| **Dysphagia** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Epigastric discomfort** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Flatulence** [†1] | | | |
| **# participants affected / at risk** | **2/60 (3.33%)** | **0/30 (0.00%)** | **2/90 (2.22%)** |
| **Food poisoning** [†1] | | | |
| **# participants affected / at risk** | **2/60 (3.33%)** | **0/30 (0.00%)** | **2/90 (2.22%)** |
| **Gastrointestinal disorder** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Gastrooesophageal reflux disease** [†1] | | | |
| **# participants affected / at risk** | **2/60 (3.33%)** | **0/30 (0.00%)** | **2/90 (2.22%)** |
| **Glossodynia** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Haematochezia** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Hiatus hernia** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Inguinal hernia** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Lip swelling** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Nausea** [†1] | | | |
| **# participants affected / at risk** | **11/60 (18.33%)** | **10/30 (33.33%)** | **21/90 (23.33%)** |
| **Oesophageal pain** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Oral mucosal blistering** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **2/30 (6.67%)** | **2/90 (2.22%)** |
| **Oral pruritus** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Paraesthesia oral** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Retching** [†1] | | | |

| | | | |
|---|---|---|---|
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Stomach discomfort † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Swollen tongue † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Toothache † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 4/30 (13.33%) | 5/90 (5.56%) |
| Vomiting † 1 | | | |
| # participants affected / at risk | 13/60 (21.67%) | 3/30 (10.00%) | 16/90 (17.78%) |
| **General disorders** | | | |
| Application site vesicles † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Asthenia † 1 | | | |
| # participants affected / at risk | 3/60 (5.00%) | 4/30 (13.33%) | 7/90 (7.78%) |
| Axillary pain † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Catheter related complication † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Catheter site pain † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Catheter site related reaction † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Chest discomfort † 1 | | | |
| # participants affected / at risk | 6/60 (10.00%) | 1/30 (3.33%) | 7/90 (7.78%) |
| Chest pain † 1 | | | |
| # participants affected / at risk | 4/60 (6.67%) | 1/30 (3.33%) | 5/90 (5.56%) |
| Chills † 1 | | | |
| # participants affected / at risk | 3/60 (5.00%) | 1/30 (3.33%) | 4/90 (4.44%) |
| Fatigue † 1 | | | |
| # participants affected / at risk | 7/60 (11.67%) | 6/30 (20.00%) | 13/90 (14.44%) |
| Feeling abnormal † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Feeling cold † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Feeling hot † 1 | | | |
| # participants affected / at risk | 3/60 (5.00%) | 2/30 (6.67%) | 5/90 (5.56%) |
| Feeling hot and cold † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Gait disturbance † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Hangover † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Influenza like illness † 1 | | | |

| | | | |
|---|---|---|---|
| # participants affected / at risk | 2/60 (3.33%) | 4/30 (13.33%) | 6/90 (6.67%) |
| Infusion site bruising [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Infusion site pain [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Infusion site paraesthesia [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Infusion site reaction [†1] | | | |
| # participants affected / at risk | 5/60 (8.33%) | 0/30 (0.00%) | 5/90 (5.56%) |
| Injection site phlebitis [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Local swelling [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 1/30 (3.33%) | 3/90 (3.33%) |
| Malaise [†1] | | | |
| # participants affected / at risk | 3/60 (5.00%) | 0/30 (0.00%) | 3/90 (3.33%) |
| Non-cardiac chest pain [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Oedema peripheral [†1] | | | |
| # participants affected / at risk | 10/60 (16.67%) | 3/30 (10.00%) | 13/90 (14.44%) |
| Pain [†1] | | | |
| # participants affected / at risk | 5/60 (8.33%) | 1/30 (3.33%) | 6/90 (6.67%) |
| Pitting oedema [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 2/30 (6.67%) | 4/90 (4.44%) |
| Puncture site haemorrhage [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Pyrexia [†1] | | | |
| # participants affected / at risk | 8/60 (13.33%) | 8/30 (26.67%) | 16/90 (17.78%) |
| Thirst [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Vessel puncture site haematoma [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| **Immune system disorders** | | | |
| Hypersensitivity [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| **Infections and infestations** | | | |
| Bronchitis [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 1/30 (3.33%) | 3/90 (3.33%) |
| Bronchopneumonia [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Cellulitis [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Cystitis [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Dermatophytosis [†1] | | | |

| | | | |
|---|---|---|---|
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Eye infection † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Folliculitis † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Fungal infection † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Fungal skin infection † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Gastroenteritis † 1 | | | |
| # participants affected / at risk | 5/60 (8.33%) | 1/30 (3.33%) | 6/90 (6.67%) |
| Gastroenteritis viral † 1 | | | |
| # participants affected / at risk | 3/60 (5.00%) | 3/30 (10.00%) | 6/90 (6.67%) |
| Gastrointestinal infection † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 2/30 (6.67%) | 2/90 (2.22%) |
| Genital infection † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Gingival infection † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Herpes simplex † 1 | | | |
| # participants affected / at risk | 4/60 (6.67%) | 3/30 (10.00%) | 7/90 (7.78%) |
| Herpes virus infection † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Influenza † 1 | | | |
| # participants affected / at risk | 5/60 (8.33%) | 7/30 (23.33%) | 12/90 (13.33%) |
| Kidney infection † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Laryngitis † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Localised infection † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Mucosal infection † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Nasopharyngitis † 1 | | | |
| # participants affected / at risk | 25/60 (41.67%) | 16/30 (53.33%) | 41/90 (45.56%) |
| Otitis media † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Postoperative wound infection † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Rash pustular † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Respiratory tract infection † 1 | | | |
| # participants affected / at risk | 3/60 (5.00%) | 0/30 (0.00%) | 3/90 (3.33%) |
| Rhinitis † 1 | | | |

| | | | |
|---|---|---|---|
| # participants affected / at risk | 0/60 (0.00%) | 2/30 (6.67%) | 2/90 (2.22%) |
| Sinusitis [†1] | | | |
| # participants affected / at risk | 4/60 (6.67%) | 4/30 (13.33%) | 8/90 (8.89%) |
| Tinea pedis [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Tonsillitis [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Tooth infection [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 1/30 (3.33%) | 3/90 (3.33%) |
| Upper respiratory tract infection [†1] | | | |
| # participants affected / at risk | 11/60 (18.33%) | 3/30 (10.00%) | 14/90 (15.56%) |
| Urinary tract infection [†1] | | | |
| # participants affected / at risk | 5/60 (8.33%) | 4/30 (13.33%) | 9/90 (10.00%) |
| Vaginal infection [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Viral infection [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 2/30 (6.67%) | 4/90 (4.44%) |
| Vulvovaginal mycotic infection [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Wound infection [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| **Injury, poisoning and procedural complications** | | | |
| Accident [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Animal bite [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Arthropod bite [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Arthropod sting [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Back injury [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Contusion [†1] | | | |
| # participants affected / at risk | 4/60 (6.67%) | 6/30 (20.00%) | 10/90 (11.11%) |
| Excoriation [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 3/30 (10.00%) | 3/90 (3.33%) |
| Fall [†1] | | | |
| # participants affected / at risk | 39/60 (65.00%) | 20/30 (66.67%) | 59/90 (65.56%) |
| Femur fracture [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Foot fracture [†1] | | | |

| | | | |
|---|---|---|---|
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Humerus fracture † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Injury † 1 | | | |
| # participants affected / at risk | 4/60 (6.67%) | 1/30 (3.33%) | 5/90 (5.56%) |
| Injury corneal † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Joint dislocation † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Joint sprain † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 2/30 (6.67%) | 3/90 (3.33%) |
| Laceration † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Ligament injury † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Limb crushing injury † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Limb injury † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Muscle strain † 1 | | | |
| # participants affected / at risk | 4/60 (6.67%) | 4/30 (13.33%) | 8/90 (8.89%) |
| Periorbital haematoma † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Procedural pain † 1 | | | |
| # participants affected / at risk | 9/60 (15.00%) | 3/30 (10.00%) | 12/90 (13.33%) |
| Repetitive strain injury † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Rib fracture † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Road traffic accident † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Skeletal injury † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Skin laceration † 1 | | | |
| # participants affected / at risk | 4/60 (6.67%) | 1/30 (3.33%) | 5/90 (5.56%) |
| Tendon injury † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Thermal burn † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 1/30 (3.33%) | 3/90 (3.33%) |
| Tooth fracture † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Traumatic ulcer † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Vaccination complication † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Wound † 1 | | | |

| | | | |
|---|---|---|---|
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| **Investigations** | | | |
| Alanine aminotransferase increased [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Aspartate aminotransferase increased [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Blood alkaline phosphatase increased [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Blood creatine phosphokinase MB increased [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Blood folate decreased [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Blood glucose increased [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Blood parathyroid hormone increased [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Blood pressure increased [†1] | | | |
| # participants affected / at risk | 3/60 (5.00%) | 1/30 (3.33%) | 4/90 (4.44%) |
| Blood thyroid stimulating hormone increased [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Blood uric acid increased [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Blood urine present [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Carbon dioxide increased [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Electrocardiogram QT corrected interval prolonged [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Eosinophil count increased [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Forced expiratory volume decreased [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Glucose urine present [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Heart rate irregular [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| International normalised ratio decreased [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Lymph node palpable [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Neutrophil count increased [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Oxygen saturation decreased [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Protein total increased [†1] | | | |

| | | | |
|---|---|---|---|
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Protein urine present † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Specific gravity urine decreased † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Urine ketone body present † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Vitamin D decreased † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Weight decreased † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Weight increased † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| White blood cell count increased † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| White blood cells urine positive † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| **Metabolism and nutrition disorders** | | | |
| Decreased appetite † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Diabetes mellitus non-insulin-dependent † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Hyperglycaemia † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Hypernatraemia † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Hypertriglyceridaemia † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Hypokalaemia † 1 | | | |
| # participants affected / at risk | 3/60 (5.00%) | 0/30 (0.00%) | 3/90 (3.33%) |
| **Musculoskeletal and connective tissue disorders** | | | |
| Arthralgia † 1 | | | |
| # participants affected / at risk | 18/60 (30.00%) | 9/30 (30.00%) | 27/90 (30.00%) |
| Back pain † 1 | | | |
| # participants affected / at risk | 14/60 (23.33%) | 7/30 (23.33%) | 21/90 (23.33%) |
| Bone pain † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Bursitis † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Buttock pain † 1 | | | |
| # participants affected / at risk | 3/60 (5.00%) | 1/30 (3.33%) | 4/90 (4.44%) |
| Costochondritis † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Exostosis † 1 | | | |

| | | | |
|---|---|---|---|
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Flank pain [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Foot deformity [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Groin pain [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Joint range of motion decreased [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Joint swelling [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Muscle atrophy [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Muscle contracture [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Muscle spasms [†1] | | | |
| # participants affected / at risk | 14/60 (23.33%) | 6/30 (20.00%) | 20/90 (22.22%) |
| Muscle tightness [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Muscle twitching [†1] | | | |
| # participants affected / at risk | 5/60 (8.33%) | 1/30 (3.33%) | 6/90 (6.67%) |
| Muscular weakness [†1] | | | |
| # participants affected / at risk | 6/60 (10.00%) | 3/30 (10.00%) | 9/90 (10.00%) |
| Musculoskeletal chest pain [†1] | | | |
| # participants affected / at risk | 5/60 (8.33%) | 1/30 (3.33%) | 6/90 (6.67%) |
| Musculoskeletal discomfort [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Musculoskeletal disorder [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Musculoskeletal pain [†1] | | | |
| # participants affected / at risk | 8/60 (13.33%) | 2/30 (6.67%) | 10/90 (11.11%) |
| Musculoskeletal stiffness [†1] | | | |
| # participants affected / at risk | 8/60 (13.33%) | 1/30 (3.33%) | 9/90 (10.00%) |
| Myalgia [†1] | | | |
| # participants affected / at risk | 12/60 (20.00%) | 5/30 (16.67%) | 17/90 (18.89%) |
| Neck pain [†1] | | | |
| # participants affected / at risk | 7/60 (11.67%) | 5/30 (16.67%) | 12/90 (13.33%) |
| Nose deformity [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Osteopenia [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |

| | | | |
|---|---|---|---|
| Osteoporosis [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Pain in extremity [†1] | | | |
| # participants affected / at risk | 15/60 (25.00%) | 7/30 (23.33%) | 22/90 (24.44%) |
| Plantar fasciitis [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Scoliosis [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Sensation of heaviness [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 1/30 (3.33%) | 3/90 (3.33%) |
| Temporomandibular joint syndrome [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Tendon pain [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Tendonitis [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 1/30 (3.33%) | 3/90 (3.33%) |
| Tenosynovitis stenosans [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| **Neoplasms benign, malignant and unspecified (incl cysts and polyps)** | | | |
| Melanocytic naevus [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| **Nervous system disorders** | | | |
| Areflexia [†1] | | | |
| # participants affected / at risk | 3/60 (5.00%) | 2/30 (6.67%) | 5/90 (5.56%) |
| Balance disorder [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Burning sensation [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Carpal tunnel syndrome [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Disturbance in attention [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Dizziness [†1] | | | |
| # participants affected / at risk | 14/60 (23.33%) | 6/30 (20.00%) | 20/90 (22.22%) |
| Dizziness postural [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Dysgeusia [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Facial palsy [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Head discomfort [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Headache [†1] | | | |

| | | | |
|---|---|---|---|
| # participants affected / at risk | 24/60 (40.00%) | 15/30 (50.00%) | 39/90 (43.33%) |
| Hyperreflexia [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Hypoaesthesia [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 2/30 (6.67%) | 4/90 (4.44%) |
| Hyporeflexia [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 1/30 (3.33%) | 3/90 (3.33%) |
| Intercostal neuralgia [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Intracranial hypotension [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Lethargy [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Loss of consciousness [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Migraine [†1] | | | |
| # participants affected / at risk | 3/60 (5.00%) | 1/30 (3.33%) | 4/90 (4.44%) |
| Nerve compression [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Paraesthesia [†1] | | | |
| # participants affected / at risk | 6/60 (10.00%) | 4/30 (13.33%) | 10/90 (11.11%) |
| Poor quality sleep [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Sinus headache [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Somnolence [†1] | | | |
| # participants affected / at risk | 3/60 (5.00%) | 0/30 (0.00%) | 3/90 (3.33%) |
| Syncope vasovagal [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Tremor [†1] | | | |
| # participants affected / at risk | 4/60 (6.67%) | 0/30 (0.00%) | 4/90 (4.44%) |
| **Psychiatric disorders** | | | |
| Abnormal dreams [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Anxiety [†1] | | | |
| # participants affected / at risk | 2/60 (3.33%) | 3/30 (10.00%) | 5/90 (5.56%) |
| Depression [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 2/30 (6.67%) | 3/90 (3.33%) |
| Insomnia [†1] | | | |
| # participants affected / at risk | 6/60 (10.00%) | 2/30 (6.67%) | 8/90 (8.89%) |
| Panic attack [†1] | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Stress [†1] | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |

| | | | |
|---|---|---|---|
| **Renal and urinary disorders** | | | |
| **Haematuria** [†1] | | | |
| **# participants affected / at risk** | **3/60 (5.00%)** | **1/30 (3.33%)** | **4/90 (4.44%)** |
| **Leukocyturia** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Nephrolithiasis** [†1] | | | |
| **# participants affected / at risk** | **3/60 (5.00%)** | **0/30 (0.00%)** | **3/90 (3.33%)** |
| **Pollakiuria** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Proteinuria** [†1] | | | |
| **# participants affected / at risk** | **2/60 (3.33%)** | **1/30 (3.33%)** | **3/90 (3.33%)** |
| **Pyuria** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **2/30 (6.67%)** | **3/90 (3.33%)** |
| **Urinary incontinence** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Urine flow decreased** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Urine odour abnormal** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **1/30 (3.33%)** | **2/90 (2.22%)** |
| **Reproductive system and breast disorders** | | | |
| **Breast pain** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Breast swelling** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Breast tenderness** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Dysmenorrhoea** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **2/30 (6.67%)** | **2/90 (2.22%)** |
| **Fibrocystic breast disease** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Genital pruritus female** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Menstrual discomfort** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Menstruation irregular** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **1/30 (3.33%)** | **2/90 (2.22%)** |
| **Scrotal cyst** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Vaginal haemorrhage** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Respiratory, thoracic and mediastinal disorders** | | | |
| **Asthma** [†1] | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Bronchospasm** [†1] | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Cough** [†1] | | | |

| | | | |
|---|---|---|---|
| # participants affected / at risk | 6/60 (10.00%) | 5/30 (16.67%) | 11/90 (12.22%) |
| Dyspnoea † 1 | | | |
| # participants affected / at risk | 7/60 (11.67%) | 4/30 (13.33%) | 11/90 (12.22%) |
| Dyspnoea exertional † 1 | | | |
| # participants affected / at risk | 4/60 (6.67%) | 0/30 (0.00%) | 4/90 (4.44%) |
| Epistaxis † 1 | | | |
| # participants affected / at risk | 3/60 (5.00%) | 0/30 (0.00%) | 3/90 (3.33%) |
| Increased bronchial secretion † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Lung disorder † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Lung infiltration † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Nasal congestion † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 2/30 (6.67%) | 4/90 (4.44%) |
| Paranasal sinus hypersecretion † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Pharyngolaryngeal pain † 1 | | | |
| # participants affected / at risk | 12/60 (20.00%) | 5/30 (16.67%) | 17/90 (18.89%) |
| Postnasal drip † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Rales † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Respiratory distress † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Respiratory failure † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Respiratory tract congestion † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 0/30 (0.00%) | 2/90 (2.22%) |
| Rhinorrhoea † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 1/30 (3.33%) | 3/90 (3.33%) |
| Sinus congestion † 1 | | | |
| # participants affected / at risk | 2/60 (3.33%) | 3/30 (10.00%) | 5/90 (5.56%) |
| Sleep apnoea syndrome † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Sneezing † 1 | | | |
| # participants affected / at risk | 0/60 (0.00%) | 1/30 (3.33%) | 1/90 (1.11%) |
| Throat irritation † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |
| Throat tightness † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 0/30 (0.00%) | 1/90 (1.11%) |
| Wheezing † 1 | | | |
| # participants affected / at risk | 1/60 (1.67%) | 1/30 (3.33%) | 2/90 (2.22%) |

| | | | |
|---|---|---|---|
| **Skin and subcutaneous tissue disorders** | | | |
| **Acne** † 1 | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Blister** † 1 | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Cold sweat** † 1 | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Decubitus ulcer** † 1 | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Dermatitis contact** † 1 | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Drug eruption** † 1 | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Ecchymosis** † 1 | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Eczema** † 1 | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **2/30 (6.67%)** | **2/90 (2.22%)** |
| **Erythema** † 1 | | | |
| **# participants affected / at risk** | **3/60 (5.00%)** | **1/30 (3.33%)** | **4/90 (4.44%)** |
| **Heat rash** † 1 | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Hyperhidrosis** † 1 | | | |
| **# participants affected / at risk** | **5/60 (8.33%)** | **0/30 (0.00%)** | **5/90 (5.56%)** |
| **Ingrowing nail** † 1 | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Photosensitivity reaction** † 1 | | | |
| **# participants affected / at risk** | **2/60 (3.33%)** | **0/30 (0.00%)** | **2/90 (2.22%)** |
| **Pruritus** † 1 | | | |
| **# participants affected / at risk** | **6/60 (10.00%)** | **1/30 (3.33%)** | **7/90 (7.78%)** |
| **Rash** † 1 | | | |
| **# participants affected / at risk** | **6/60 (10.00%)** | **3/30 (10.00%)** | **9/90 (10.00%)** |
| **Rash macular** † 1 | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Rash maculo-papular** † 1 | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Rash papular** † 1 | | | |
| **# participants affected / at risk** | **3/60 (5.00%)** | **0/30 (0.00%)** | **3/90 (3.33%)** |
| **Rash pruritic** † 1 | | | |
| **# participants affected / at risk** | **4/60 (6.67%)** | **1/30 (3.33%)** | **5/90 (5.56%)** |
| **Skin burning sensation** † 1 | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Skin lesion** † 1 | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Skin nodule** † 1 | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Skin odour abnormal** † 1 | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |

| | | | |
|---|---|---|---|
| **Skin warm † 1** | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Subcutaneous nodule † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Telangiectasia † 1** | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Urticaria † 1** | | | |
| **# participants affected / at risk** | **6/60 (10.00%)** | **0/30 (0.00%)** | **6/90 (6.67%)** |
| **Vascular disorders** | | | |
| **Aneurysm † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Diastolic hypotension † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |
| **Flushing † 1** | | | |
| **# participants affected / at risk** | **3/60 (5.00%)** | **2/30 (6.67%)** | **5/90 (5.56%)** |
| **Haematoma † 1** | | | |
| **# participants affected / at risk** | **2/60 (3.33%)** | **0/30 (0.00%)** | **2/90 (2.22%)** |
| **Hot flush † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **1/30 (3.33%)** | **2/90 (2.22%)** |
| **Hypertension † 1** | | | |
| **# participants affected / at risk** | **3/60 (5.00%)** | **1/30 (3.33%)** | **4/90 (4.44%)** |
| **Hypotension † 1** | | | |
| **# participants affected / at risk** | **2/60 (3.33%)** | **1/30 (3.33%)** | **3/90 (3.33%)** |
| **Phlebitis † 1** | | | |
| **# participants affected / at risk** | **0/60 (0.00%)** | **1/30 (3.33%)** | **1/90 (1.11%)** |
| **Raynaud's phenomenon † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **1/30 (3.33%)** | **2/90 (2.22%)** |
| **Vasoconstriction † 1** | | | |
| **# participants affected / at risk** | **1/60 (1.67%)** | **0/30 (0.00%)** | **1/90 (1.11%)** |

† Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 9.1

## More Information

Hide More Information

**Certain Agreements:**

| |
|---|
| Principal Investigators are **NOT** employed by the organization sponsoring the study. |
| There **IS** an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. |
| The agreement is:<br>☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **less than or equal to 60 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.<br>☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **more than 60 days but less than or equal to 180 days**. The sponsor cannot require changes to the communication and cannot extend the embargo. |

Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

☑ **Restriction Description:** In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.

**Limitations and Caveats**

| **Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data** |
|---|
| No text entered. |

**Results Point of Contact:**

Name/Title: Genzyme Medical Information
Organization: Genzyme Corporation
phone: 800-745-4447

**No publications provided by Genzyme**

**Publications automatically indexed to this study:**

van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010 Apr 15;362(15):1396-406.

| | |
|---|---|
| Responsible Party: | Genzyme Corporation ( Medical Monitor ) |
| ClinicalTrials.gov Identifier: | NCT00158600 History of Changes |
| Other Study ID Numbers: | AGLU02704, 2005-002759-42 |
| Study First Received: | September 8, 2005 |
| Results First Received: | June 24, 2010 |
| Last Updated: | June 24, 2010 |
| Health Authority: | United States: Food and Drug Administration; European Union: European Medicines Agency; France: Afssaps - French Health Products Safety Agency; Netherlands: College ter Beoordeling van Geneesmiddelen Medicines Evaluation Board (CBGMEB) |